Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $14.64 Average Price Target from Analysts

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) have received a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $15.27.

A number of analysts recently commented on the stock. Barclays lifted their target price on shares of Travere Therapeutics from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Piper Sandler lifted their target price on shares of Travere Therapeutics from $11.00 to $12.00 and gave the stock a “neutral” rating in a research note on Friday, August 2nd. Canaccord Genuity Group lifted their target price on shares of Travere Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Wedbush lifted their target price on shares of Travere Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Finally, HC Wainwright lifted their target price on shares of Travere Therapeutics from $19.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday.

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC grew its holdings in shares of Travere Therapeutics by 1,656.4% during the fourth quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock worth $27,000 after buying an additional 2,849 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Travere Therapeutics during the first quarter worth $32,000. Nisa Investment Advisors LLC grew its holdings in shares of Travere Therapeutics by 968.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,650 shares of the company’s stock worth $51,000 after buying an additional 5,121 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Travere Therapeutics by 353.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,690 shares of the company’s stock valued at $78,000 after purchasing an additional 6,773 shares during the period. Finally, Quest Partners LLC grew its holdings in shares of Travere Therapeutics by 240.6% in the second quarter. Quest Partners LLC now owns 14,336 shares of the company’s stock valued at $118,000 after purchasing an additional 10,127 shares during the period.

Travere Therapeutics Stock Up 1.3 %

Shares of Travere Therapeutics stock opened at $8.53 on Friday. The company has a debt-to-equity ratio of 5.10, a current ratio of 2.78 and a quick ratio of 2.75. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $15.90. The firm’s 50-day moving average is $8.51 and its two-hundred day moving average is $7.75. The stock has a market cap of $649.38 million, a price-to-earnings ratio of -4.06 and a beta of 0.77.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Monday, May 6th. The company reported ($1.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 207.40%. The firm had revenue of $41.40 million during the quarter, compared to the consensus estimate of $43.46 million. During the same quarter in the prior year, the business posted ($1.27) earnings per share. The firm’s quarterly revenue was up 34.0% on a year-over-year basis. As a group, research analysts expect that Travere Therapeutics will post -3.92 earnings per share for the current fiscal year.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.